Dipeptide Diaminobutyroyl Benzylamide Diacetate

Dipeptide diaminobutyroyl benzylamide diacetate is a tripeptide (a three amino acid peptide) with molecular weight less than 500 Da, meaning that it's small enough to penetrate nicely and easily into the skin.

1. C-Peptide replacement therapy and sensory nerve function in type 1 diabetic neuropathy

2. Investigating Potential Interactions Between Neurohypophyseal Peptides, their Drug Analogs, and Coagulation Factor VIII

3. Emu oil in combination with other active ingredients for treating skin imperfections

4. cRGD-functionalized, DOX-conjugated, and 64Cu-labeled superparamagnetic iron oxide nanoparticles for targeted anticancer drug delivery and PET/MR imaging

5. Constitutive and inflammation-dependent antimicrobial peptides produced by epithelium are differentially processed and inactivated by the commensal Finegoldia magna and the pathogen Streptococcus pyogenes

Another peptide, unrelated to collagen synthesis and degradation, was formulated into the line treatment to target neuromuscular activity. Dipeptide diaminobutyroyl benzylamide diacetate was developed to mimic Waglerin-1, a compound found in temple viper snake venom. Waglerin-1 has been shown to block the nicotinic acetylcholine receptors at the neuromuscular junction, thus inhibiting muscular movement. The function of the Wagerlin-1-mimicking peptide is important for the treatment of lines since facial areas associated with repeated muscle movement are especially susceptible to wrinkle formation.

Trookman, N. S., Rizer, R. L., Ford, R., Ho, E., & Gotz, V. (2009). Immediate and long-term clinical benefits of a topical treatment for facial lines and wrinkles. The Journal of clinical and aesthetic dermatology, 2(3), 38.